Cell-free Circulating DNA in Primary Cutaneous Lymphomas
- Conditions
- Lymphoma, Large B-cell, DiffuseMycosis Fungoides
- Interventions
- Genetic: Cytogenetic and molecular studies
- Registration Number
- NCT02883517
- Lead Sponsor
- University Hospital, Bordeaux
- Brief Summary
To evaluate the possibility of detecting cell-free circulating tumoral DNA in potentially aggressive primary cutaneous lymphomas, the investigator opted to search a representative tumor sample mutation in the blood of these patients, by digital PCR. Patients with mycosis fungoides, primary cutaneous T-cell lymphoma helper follicular phenotype and primary cutaneous diffuse large B-cell lymphoma, leg-type will be included and 4 blood samples will be collected during 12 months.
- Detailed Description
Primary cutaneous lymphomas represent the second extra nodal localization of lymphomas, and are constituted by T-cell and B-cell phenotype lymphomas. Mycosis fungoides, a T-cell epidermotropic lymphoma, is the most frequent. Its clinical behavior is usually indolent but some patients have an aggressive evolution. Among B-cell cutaneous lymphomas, primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT) is the most aggressive. Cytogenetic and molecular studies on these tumours led to a genetic characterization of these entities. Therefore, there is not any biologic marker that can help monitoring these lymphomas. In solid tumors, mutations exhibited by the tumour tissue has been detected in plasma of patients, assessing the possibility to detect cell-free circulating tumoral DNA in a blood sample, with correlations with clinical characteristics and metastatic outcome. The concept of liquid biopsies, allowing the detection of tumour mutation in plasma has been validated in nodal diffuse large B-cell lymphoma. That's why the purpose is to evaluate the possibility to detect cell-free circulating tumoral DNA in primary cutaneous lymphomas, using a highly sensitive method (digital PCR), combined with a next generation sequencing panel of the tumour sample.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 35
- age > 18 years;
- French social security system affiliation or equivalent;
- Patient with an aggressive cutaneous lymphoma (PCDLBCL-LT, mycosis fungoides, T helper follicular cutaneous lymphoma) diagnosed and monitored at the university hospital of Bordeaux;
- Written and informed consent obtained for genetic blood test;
- Biopsy sample available for molecular analysis.
- Another cancer (except "in situ" and surgery treated cutaneous carcinomas) in the precedent 5 years.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Aggressive primary cutaneous lymphomas Cytogenetic and molecular studies * Mycosis fungoides ≥ T2b * Primary cutaneous T helper follicular lymphoma ≥ T2 * Primary cutaneous diffuse large B-cell lymphoma, leg type Genetic: Cytogenetic and molecular studies Detect cell-free circulating tumoral DNA in a blood sample, with correlations with clinical characteristics and metastatic outcome.
- Primary Outcome Measures
Name Time Method Proportion of patients who have circulating free tumor DNA (detected by Digital polymerase chain reaction) with the mutation identified on biopsy Week 36
- Secondary Outcome Measures
Name Time Method Amount of free circulating DNA (number of copies / µl) Day 1 Amount of circulating tumor DNA (number of copies / µl) Day 1 Number of patient with presence or absence of blood lymphocyte clone identical to the tumor clone Week 36 Number of patient with presence or absence of mutation identified in circulating blood Week 36
Trial Locations
- Locations (1)
University Hospital of Bordeaux - Hospital Saint André
🇫🇷Bordeaux, France